Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Peter van Tintelen

Showing results (201-210 of 232) with videos related to

Pageof 24
Sort By:
Genome Medicine|September 18, 2023
Identification of novel genetic risk factors of dilated cardiomyopathy: from canine to humanJulia E Niskanen, Åsa Ohlsson, Ingrid Ljungvall, et al.
European Heart Journal|October 27, 2015
Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriersGodelieve R F Claes, Florence H J van Tienen, Patrick Lindsey, et al.
Circulation. Cardiovascular Genetics|August 10, 2017
<i>Lamin A/C</i>-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder MutationEdgar T Hoorntje, Ilse A Bollen, Daniela Q Barge-Schaapveld, et al.
Heart Rhythm|November 3, 2019
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summaryJeffrey A Towbin, William J McKenna, Dominic J Abrams, et al.
Circulation. Genomic and Precision Medicine|May 22, 2019
Mortality Risk Associated With Truncating Founder Mutations in TitinMark Jansen, Annette F Baas, Karin Y van Spaendonck-Zwarts, et al.
Heart Rhythm|May 13, 2019
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathyJeffrey A Towbin, William J McKenna, Dominic J Abrams, et al.
Circulation. Cardiovascular Genetics|March 31, 2015
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family MembersJudith A Groeneweg, Aditya Bhonsale, Cynthia A James, et al.
Journal of the American College of Cardiology|February 6, 2016
Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric CardiomyopathyRowida Almomani, Judith M A Verhagen, Johanna C Herkert, et al.
Circulation. Arrhythmia and Electrophysiology|January 29, 2026
Left Ventricular Late Gadolinium Enhancement for Arrhythmic Risk Prediction in ARVCCorrado De Marco, Babken Asatryan, Anneline S J M Te Riele, et al.
Circulation|September 30, 2021
Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating VariantsMarta Gigli, Davide Stolfo, Sharon L Graw, et al.
Pageof 24

Showing results (201-210 of 232) with videos related to

Sort By:
Pageof 24
Genome Medicine|September 18, 2023
Identification of novel genetic risk factors of dilated cardiomyopathy: from canine to humanJulia E Niskanen, Åsa Ohlsson, Ingrid Ljungvall, et al.
European Heart Journal|October 27, 2015
Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriersGodelieve R F Claes, Florence H J van Tienen, Patrick Lindsey, et al.
Circulation. Cardiovascular Genetics|August 10, 2017
<i>Lamin A/C</i>-Related Cardiac Disease: Late Onset With a Variable and Mild Phenotype in a Large Cohort of Patients With the Lamin A/C p.(Arg331Gln) Founder MutationEdgar T Hoorntje, Ilse A Bollen, Daniela Q Barge-Schaapveld, et al.
Heart Rhythm|November 3, 2019
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summaryJeffrey A Towbin, William J McKenna, Dominic J Abrams, et al.
Circulation. Genomic and Precision Medicine|May 22, 2019
Mortality Risk Associated With Truncating Founder Mutations in TitinMark Jansen, Annette F Baas, Karin Y van Spaendonck-Zwarts, et al.
Heart Rhythm|May 13, 2019
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathyJeffrey A Towbin, William J McKenna, Dominic J Abrams, et al.
Circulation. Cardiovascular Genetics|March 31, 2015
Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Patients and Family MembersJudith A Groeneweg, Aditya Bhonsale, Cynthia A James, et al.
Journal of the American College of Cardiology|February 6, 2016
Biallelic Truncating Mutations in ALPK3 Cause Severe Pediatric CardiomyopathyRowida Almomani, Judith M A Verhagen, Johanna C Herkert, et al.
Circulation. Arrhythmia and Electrophysiology|January 29, 2026
Left Ventricular Late Gadolinium Enhancement for Arrhythmic Risk Prediction in ARVCCorrado De Marco, Babken Asatryan, Anneline S J M Te Riele, et al.
Circulation|September 30, 2021
Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating VariantsMarta Gigli, Davide Stolfo, Sharon L Graw, et al.
Pageof 24